TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06683599

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apneic oxygenation
Description: 1 L/kg/min FiO2 1.0 low-flow nasal supplemental oxygen with conventional nasal cannula during tracheal intubation performed with a video laryngoscope with Miller-blade or Macintosh-blade size No. 0 or No. 1.
Study: NCT06402565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX1416 plus SOC
Description: Topical Nitric Oxide

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus SOC
Description: Placebo plus SOC as provided in the Arm/Group description.
Study: NCT06709404

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Receive telehealth navigation intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic health record review
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic health record review
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard caregiving experience
Study: NCT06717152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SJP-0132
Description: Aqueous eye drop, one drop each time and four times each day, 8 weeks in treatment period in SJP-0132 group.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Aqueous eye drop, one drop each time and four times each day, 2 weeks in run-in period in both groups and 8 weeks in treatment period in placebo group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Aqueous eye drop, one drop each time and four times each day, 2 weeks in run-in period in both groups and 8 weeks in treatment period in placebo group.
Study: NCT04939363

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Obinutuzumab with Ibrutinib and Venetoclax
Description: 1. Obinutuzumab intravenous infusion:~2. Ibrutinib PO 560mg daily starting on cycle 1 day 1 for 12 cycles.~3. Venetoclax with an accelerated ramp-up and close inpatient Tumor Lysis Syndromes (TLS) monitoring starts on cycle 1 day 15 to the target dose of 400mg daily for a total of 12 cycles:
Study: NCT06714851

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chondractiv Move
Description: The dietary supplement under study (Chondractiv Move) is a combination of 2 active ingredients: Hydrolyzed chicken cartilage and Rosehip extract at the dose of 1580 mg/day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains 100% maltodextrins as non-active agent at the dose of 1800 mg/day.
Study: NCT06729138

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resisted Sprint Training
Description: In this intervention, participants will perform 16 sessions of resisted sprint training with external loads using a sled over eight weeks. In these 16 sessions the intensity will vary in both the distance to be covered and the load to be moved.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sprint Training
Description: In this intervention, participants will perform 16 sessions of sprint training over eight weeks. In these 16 sessions the intensity will vary in the distance.
Study: NCT06728644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-arginine intervention
Description: L-arginine intervention for 3 months, 3 g per day.
Study: NCT06729489

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Upper Endoscopy
Description: Endoscopy in children with refractory iron deficiency anemia
Study: NCT06727968

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Compression Stocking
Description: Wear the compression stockin at least 6-8 hours/day

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Compression Stocking
Description: Wear the compression stockin at least 6-8 hours/day

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Description: Home-based exercise programm based on calf strengthening, mobility and stretching of lower limbs performed in standing, sitting, and laying position. Each exercise was performed 15-20 repetitions, 1 set, 3-4 days at week. In addition to these exercises, patients were instructed to walk, at least, 20 minutes at day.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Self-massage
Description: Self-massage techniques alterne manual lymphatic drainage maneuvers with superficial techniques that follow the path of saphenous veins, their respective cayaids and the anastomotic system.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prevention measures
Description: General preventive recommendations, and they were explained to the patient by the primary care physician. Those recommendations were based on the reduction in risk factors described in the Guide of Recommendations for the management of Chronic Venous Disease in Primary Care published by Semergen and semFYC.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prevention measures
Description: General preventive recommendations, and they were explained to the patient by the primary care physician. Those recommendations were based on the reduction in risk factors described in the Guide of Recommendations for the management of Chronic Venous Disease in Primary Care published by Semergen and semFYC.
Study: NCT06729684

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: digital health (application and smartwatch)
Description: The application allows users to conduct self-assessments for managing symptoms and side effects related to treatment. Based on the assessment results, it provides personalized self-management strategies. Additionally, users can access features for exercise, diet, and weight management.
Study: NCT06728514

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block group.
Description: In ESPB technique the linear transducer will be placed over the spinous process of the vertebra and a point 3 cm lateral to it are marked at the T10-T11 level before performing the block. Under aseptic precautions, the 23G spinal needle is inserted and advanced perpendicular to the skin in all planes to contact the transverse process of the vertebra. The transverse process of the thoracic vertebra lies at a variable depth of 2-4 cm from the skin depending on the build of the individual. At this point, the needle tip lies between the erector spinae muscle and transverse process. After negative aspiration, local anesthetic is injected in 3-5 ml aliquots. A volume of 20-25 ml of 0.25% bupivacaine will be used for analgesia on each side depending upon the surgery and requirements. The number of attempts will be noted.Time taken to perform block in minutes will be noted from placing transducer to taking out needle after injecting drug in plane.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paravertebral Nerve Block
Description: In PVB technique the patient will be placed in the lateral position, and the superior aspect of the T9,T10 and T11 spinous processes will be identified. Under complete aseptic precautions and after skin infiltration with LA, 23G spinal needle will be inserted perpendicular to the skin, with the goal of contacting the tranverse process. Once the TP is contacted, generally at a depth of 2 to 5 cm in adults, the needle is withdrawn into the subcutaneous tissue, redirected in a caudal direction, and then slowly advanced with the purpose of entering the PVS at an approximate depth of 1.0 to 1.5 cm past the initial contact with the TP. After perforating the costotransverse ligament and negative aspiration for blood, air, or spinal fluid,10 mL of 0.25% bupivacaine will be injected at each level superficial to to the pleural line. Displacement of the pleura line anteriorly will be confirmed proper injection of the local anaesthetic solution. The number of attempts will be noted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inj Bupivacaine
Description: Inj Bupivacaine 0.25% (10ml) in both groups

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inj Bupivacaine
Description: Inj Bupivacaine 0.25% (10ml) in both groups
Study: NCT06729216

Intervention type: DIAGNOSTIC_TEST
Intervention: Antifungal susceptibility testing (AFST)
Description: testing the fungal susceptibility to different drugs
Study: NCT05267340

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TARA
Description: This will be a 12-week group meditation training - Training for Awareness, Resilience, and Action (TARA)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psycho-Education
Description: This will be a 12-week group meditation training - Training for Awareness, Resilience, and Action (TARA) without the mindfulness meditation components
Study: NCT05438940

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitbit Data Collection
Description: Participants will log food intake while sharing their data with a dietician in real time for 12 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Counseling
Description: Participants will receive individually tailored, bi-weekly nutrition counseling from a dietician via telehealth

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Survey
Description: Participants will take a survey at baseline and weeks 4,8,12 \& 16. (FACT-G) Questionnaire includes questions about participant's physical, social, emotional and functional well being over the past 7 days. This questionnaire uses a 5 point Likert-type scale, 0=not at all, 4=very much. A higher total score indicates better quality of life.
Study: NCT06444815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VET3-TGI
Description: Oncolytic vaccinia virus engineered with immunomodulatory transgenes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VET3-TGI
Description: Oncolytic vaccinia virus engineered with immunomodulatory transgenes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VET3-TGI
Description: Oncolytic vaccinia virus engineered with immunomodulatory transgenes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VET3-TGI
Description: Oncolytic vaccinia virus engineered with immunomodulatory transgenes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: anti-pd1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: anti-pd1 antibody
Study: NCT04928781

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Counseling
Description: Smoking cessation counseling will be provided following standards set by the institution patients are receiving care at (Dartmouth-Hitchcock Medical Center).
Study: NCT06244368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GVM±R regimen
Description: Mitoxantrone hydrochloride liposome (18 mg/m\^2) on day 1； Gemcitabine (800 mg/m\^2) on day 1,8； Vinorelbine (20mg/m\^2) on day 1,8； Rituximab (375mg/m\^2) on day 1;~The regimen will be administered every 3 weeks, for a maximum of 6 cycles. The choice of CD20 monoclonal antibody will be determined by the attending physician.
Study: NCT06378424

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Application
Description: Before peripheral intravenous catheterization, heat of approximately 40-42 o C was applied for 1 minute to the area of the procedure using a hot pack, which is one of the dry heat application methods. The heat application pack has a feature that it can maintain its temperature when taken out of hot water and does not disturb the person when it comes into direct contact with the skin. In order to apply heat to the individuals in this group, a pack of 11 x 19 cm is used. This pack is covered with cloth and contains a non-toxic gel, and is placed in hot water to prepare it for use. Because this pack is reusable, it was disinfected before and after each use.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat Application
Description: Before peripheral intravenous catheterization, heat of approximately 40-42 o C was applied for 1 minute to the area of the procedure using a hot pack, which is one of the dry heat application methods. The heat application pack has a feature that it can maintain its temperature when taken out of hot water and does not disturb the person when it comes into direct contact with the skin. In order to apply heat to the individuals in this group, a pack of 11 x 19 cm is used. This pack is covered with cloth and contains a non-toxic gel, and is placed in hot water to prepare it for use. Because this pack is reusable, it was disinfected before and after each use.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vibration Application
Description: With individuals in this group, the Buzzy® device was used to provide vibration. The Buzzy® device, at room temperature, was placed by the researcher on the peripheral intravenous catheterization application area before the application was performed. For one minute before the application, a slight, non-discomforting vibration was applied to the intervention area. As the Buzzy® device can be used more than once, it was disinfected after each use and before being used with another individual. In this study, the body of the device was used, and only vibration was applied to the individuals in this group.
Study: NCT04881812

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-Coated Balloons
Description: Percutaneous coronary intervention of residual disease adjacent to a chronic total occlusion with a paclitaxel drug-coated balloon (minimal stenting strategy).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug-Eluting-Stent
Description: Percutaneous coronary intervention of the chronic total occlusion and residual coronary artery disease with an everolimus-eluting platinum chromium coronary stent (complete stenting strategy).
Study: NCT05374447

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endobronchial Ultrasound-Guided Intranodal Forceps Biopsy
Description: Patients with mediastinal adenopathy will undergo EBUS-IFB and EBUS-TBNA during the same procedure to compare the yield of this procedure with EBUS-TBNA alone.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endobronchial Ultrasound-Guided Intranodal Forceps Biopsy
Description: Patients with mediastinal adenopathy will undergo EBUS-IFB and EBUS-TBNA during the same procedure to compare the yield of this procedure with EBUS-TBNA alone.
Study: NCT05947253

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Buyteko breathing technique
Description: group A 20 participants received Buyteko breathing technique 2 session for 3 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: active cycle of breathing technique
Description: Group B 20 participants received active cycle of breathing technique 2 session for 3 weeks
Study: NCT04214210

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted Family Gene Toolkit
Description: Five web-based modules designed to increase knowledge of cancer genetics (Module 1); provide decisional support for genetic testing (Module 2); increase active coping to common challenges faced by HBOC families (Module 3); provide a five-steps, skills-building communication training (Module 4); increase knowledge about management of hereditary cancer risk based on the most updated recommendations from the National Comprehensive Cancer Network (Module 5).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Targeted intervention
Description: The comparison website will provide targeted information about HBOC and enable sharing genetic test results.The Korean team will define the contents of the comparison website that will mimic the structure and function of a website already available in the US. The Korean team will create a translation process protocol, and share this guide for further translations from English into Korean and three Swiss national languages. The tailored and the targeted platform will be technically implemented in the same system, to track access and usage of the platform and provide a user-friendly experience.
Study: NCT05031442

Intervention type: DEVICE
Group type: OTHER
Intervention: RH1 (low waist)
Description: Investigational product variant 1 low waist

Intervention type: DEVICE
Group type: OTHER
Intervention: RH1 (low waist)
Description: Investigational product variant 1 low waist

Intervention type: DEVICE
Group type: OTHER
Intervention: Reference variant 1 (low waist)
Description: Reference product variant 1

Intervention type: DEVICE
Group type: OTHER
Intervention: Reference variant 1 (low waist)
Description: Reference product variant 1

Intervention type: DEVICE
Group type: OTHER
Intervention: RC2 (high waist)
Description: Investigational product variant 2 high waist

Intervention type: DEVICE
Group type: OTHER
Intervention: RC2 (high waist)
Description: Investigational product variant 2 high waist

Intervention type: DEVICE
Group type: OTHER
Intervention: Reference variant 2 (high waist)
Description: Reference product variant 2

Intervention type: DEVICE
Group type: OTHER
Intervention: Reference variant 2 (high waist)
Description: Reference product variant 2
Study: NCT05750758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivaroxaban
Description: rivaroxaban 2.5mg bid for 1m
Study: NCT05178472

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Description: Receive SOC immunotherapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Immunotherapy
Description: Receive SOC immunotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo SRS

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Radiosurgery
Description: Undergo SRS

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vertebroplasty
Description: Undergo vertebroplasty
Study: NCT05900375

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Decision Aid
Description: A paper parent decision aid in color will be provided to all patients at the time of their appointment and will aid in discussion with health care professionals.
Study: NCT04492449

Intervention type: OTHER
Intervention: congenital malformation
Description: congenital malformation

Intervention type: OTHER
Intervention: congenital malformation
Description: congenital malformation
Study: NCT06426212

Intervention type: DRUG
Intervention: Use of teicoplanin three times a week
Description: retrospective study to evaluate the clinical effectiveness of teicoplanin therapy according to a three-weekly scheme comparing its use in the treatment of deep infections (deep seated infections - DSIs) and superficial infections (non-deep seated infections - NDSIs).

Intervention type: DRUG
Intervention: Use of teicoplanin three times a week
Description: retrospective study to evaluate the clinical effectiveness of teicoplanin therapy according to a three-weekly scheme comparing its use in the treatment of deep infections (deep seated infections - DSIs) and superficial infections (non-deep seated infections - NDSIs).
Study: NCT05199987

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Occupational Therapy
Description: Standard occupational therapy sessions include patient therapeutic education (implementation of strategies and/or technical aids promoting autonomy and independence), walking and stair exercises in real-life conditions (weighted shopping bag, unstable ground, ...), as well as work on activities of daily living aiming to improve toileting skills (includes individual assessment, the use of technical aids depending of this assessment, and personalised strategies to conserve energy).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational Therapy with Breathing Control Exercises
Description: Includes the same treatment than the one described in standard occupation therapy but with the addition of 30-minute sessions per day on breathing control exercises. These exercises included the reproduction of gestures reproducing daily activities and simultaneous explanations of breathing techniques that the patient can perform in order to set up strategies for saving breath during exercise.
Study: NCT05116917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 3 mg/kg (up to 240 mg maximum) will be given on day 1 (± 3 days) of each 14-day treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 1 mg/kg will be given on day 1 cycle 1 (± 3 days) and once more after 6 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Description: Seasonal influenza vaccine is given IM or via PharmaJet Stratis Needle-Free Injection System, 0.5 mL per dose as a single on day 1 cycle 1 (± 3 days)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: * A total dose of 15 Gy as a single fraction is prescribed as the mean dose to the PTV.~* PTV should be covered by 95% isodose (PTV D99% \> 95%).
Study: NCT04486118

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril Pills
Description: Tablets will be taken by oral administration daily, based on titration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Benazepril Pill
Description: Tablets will be taken by oral administration daily, based on titration
Study: NCT05229328

Intervention type: DIAGNOSTIC_TEST
Intervention: Peripheral blood test
Description: Collect peripheral blood to separate and extract plasma, PBMC, and plasma exosomal miRNA, and sequence to find indicators related to disease deterioration and prognosis

Intervention type: DIAGNOSTIC_TEST
Intervention: Peripheral blood test
Description: Collect peripheral blood to separate and extract plasma, PBMC, and plasma exosomal miRNA, and sequence to find indicators related to disease deterioration and prognosis

Intervention type: DIAGNOSTIC_TEST
Intervention: Peripheral blood test
Description: Collect peripheral blood to separate and extract plasma, PBMC, and plasma exosomal miRNA, and sequence to find indicators related to disease deterioration and prognosis
Study: NCT05691946

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kinesiology Taping
Description: The experimental group was applied 'Y shaped' kinesiology taping on gastro-soleus muscle group, based on facilitation technique with 25-50% stretching.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Taping
Description: The placebo group was applied kinesiology taping on gastro-soleus muscle group without any stretching.